Knowledge Management Implementation - The authors discuss the technology and guidance required to achieve good knowledge management in a biopharmaceutical company. - BioPharm International

ADVERTISEMENT

Knowledge Management Implementation
The authors discuss the technology and guidance required to achieve good knowledge management in a biopharmaceutical company.


BioPharm International
pp. 50-55

CONCLUSION

A KM initiative is a major concern for biopharmaceutical companies worldwide. The major objective of this article is to present the conceptual implementation of a KM framework for the biopharmaceutical industry. The framework, when implemented, will enable effective storage and handling of knowledge developed within the organization. This will also lead to more efficient process implementation within an organization as the knowledge thus achieved can be applied synergically throughout the organization when needed. This could go a long way in dealing with the various challenges being faced by biopharmaceutical companies.

Tarun Jain* is an assistant systems engineer and Bipul Pandey is an assistant systems engineer at Tata Consultancy Services, New Delhi, India. *To whom correspondence should be addressed,
.

PEER REVIEWED

Article submitted: Oct. 25, 2011.
Article accepted: Dec. 5, 2011.

REFERENCES

1. J. Liebowitz and T. Beckman, Knowledge organizations: What every Manager Should Know, (St. Luice Press, Boca Raton, FL, 1998).

2. T. Davenport and L. Prusak, Working Knowledge: How Do Organizations Manage What They Know?, (Harvard Business School Press, Boston, MA, 1998).

3. C.H. Tsai, C.L. Chang, and L. Chen, International Journal of the Computer, the Internet and Management 14 (3), 60–78 (2006).

4. Y. Malhotra, Information Strategy: The Executive's Journal, 16 (4), 5–16 (2000).

5. M. Lytras, A. Pouloudi, and A. Poulymenakou, J. Knowledge Management, 6 (1), 40–51 (2002).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here